Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors
The purpose of this signal seeking study was to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.
Inclusion Criteria:
Exclusion Criteria:
Little Rock, Arkansas 72205, United States
Sacramento, California 95817, United States
New Haven, Connecticut 06520, United States
South Bend, Indiana 46617, United States
Ann Arbor, Michigan 48109 5271, United States
Grand Rapids, Michigan 49546, United States
Kansas City, Missouri 64111, United States
Las Vegas, Nevada 89109, United States
Chapel Hill, North Carolina 27599-7600, United States
Portland, Oregon 97239, United States
Sioux Falls, South Dakota 57104, United States
Chattanooga, Tennessee 37404, United States
Houston, Texas 77030, United States
San Antonio, Texas 78229, United States
Kennewick, Washington 99336, United States